We serve 1-((4-Aminobenzenemethane)sulfonyl)pyrrolidine CAS:334981-10-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: 1-((4-Aminobenzenemethane)sulfonyl)pyrrolidine
CAS.NO: 334981-10-1
Synonyms:4-(pyrrolidin-1-ylsulfonylmethyl)aniline
1-[(4-Aminobenzyl)sulfonyl]pyrrolidine
4-[(1-Pyrrolidinylsulfonyl)methyl]aniline
Molecular Formula: C11H16N2O2S
Molecular Weight: 240.32200
Physical and Chemical Properties:
Density: 1.31 g/cm3
Boiling point:434.2ºC at 760 mmHg
Melting point: 170-176ºC
Flash point: 216.4±29.3 °C
Refractive index: 1.618
Specification:
Appearance: Pale yellow solid
Purity: 98％
Packing:
25kg 1 cardboard drum or according to customer specified requirements
Storage:Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Application:Intermediates of Almotriptan malate CAS:181183-52-8.
Contact us for information like 1-((4-Aminobenzenemethane)sulfonyl)pyrrolidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-[(1-Pyrrolidinylsulfonyl)methyl]aniline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-((4-Aminobenzenemethane)sulfonyl)pyrrolidine Use and application,4-(pyrrolidin-1-ylsulfonylmethyl)aniline technical grade,usp/ep/jp grade.
Related News: The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses.Methyl malonyl chloride manufacturer Countries across Asia, Europe, Australia and North America have also had confirmed cases, including the UK.3-Bromo-4-fluorobenzotrifluoride supplier Countries across Asia, Europe, Australia and North America have also had confirmed cases, including the UK.1-bromo-2-(bromomethyl)benzene vendor From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity.”This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.
